Arcadia Biosciences Seeks Stockholder Nod for Reverse Split to Dodge Nasdaq Delisting and Unlock $3.5M Warrant Exercise
RKDA is trading near its 52-week low of $0.59 (5.1% above the low).
Summary
Arcadia Biosciences files preliminary proxy seeking stockholder approval for a reverse stock split to cure a Nasdaq bid price deficiency and for the issuance of shares underlying Series A-1 warrants from its June 2026 private placement, which would provide approximately $3.5 million in additional capital.
Key Events · Corporate Governance and Compliance · RKDA
-
Reverse Stock Split Proposed
To lift the stock price above $1.00 and cure a Nasdaq deficiency, the board seeks authority to implement a reverse stock split at a ratio between 1-for-2 and 1-for-10.
-
Issuance Proposal for Series A-1 Warrants
Stockholder approval is sought for the issuance of up to 3,883,496 shares upon exercise of Series A-1 Preferred Investment Options from the June 2026 private placement, which would yield approximately $3.5 million in gross proceeds at $0.91 per share.
-
Nasdaq Delisting Risk
After its stock traded below $1.00 for 30 consecutive business days, the company received a deficiency letter from Nasdaq; it has 180 days to regain compliance, and the reverse split is the primary mechanism to achieve this.
-
Critical Cash Need
With only $954,000 in cash as of March 31, 2026 and a going concern warning, the $3.5 million from warrant exercises is essential to fund operations; failure to approve the issuance proposal would cut off this capital source.
Analysis · RKDA · Energy & Transportation
With its stock at $0.62 and a Nasdaq delisting notice for sub-$1.00 bid price, Arcadia Biosciences is asking stockholders to approve a reverse stock split at a ratio between 1-for-2 and 1-for-10. The company also seeks approval to issue up to 3.88 million shares upon exercise of Series A-1 warrants from its June 2026 private placement, which would bring in roughly $3.5 million in additional capital. Both proposals are critical: the reverse split is the primary tool to regain Nasdaq compliance and avoid delisting, while the warrant exercise approval unlocks cash that the company—with only $954,000 on hand as of March 31, 2026 and a going concern warning—urgently needs. The proxy also includes a new equity incentive plan and routine governance items, but the reverse split and issuance proposals are the ones that will determine whether Arcadia can stay listed and funded.
How filings like this one have moved
In the 30 days to Oct 16, 2026, 44.7% of the 302 measured filings Wiseek scored 9 moved their stock by 5% or more by the next session's close. The median move was -0.26%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, RKDA was trading at $0.62 on NASDAQ in the Energy & Transportation sector, with a market capitalization of approximately $1.4M. The 52-week trading range was $0.59 to $6.71. This filing was assessed with negative market sentiment and an importance score of 9 out of 10.